Schroder Investment Management Group’s CRISPR Therapeutics CRSP Stock Holding History

Schroder Investment Management Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23,000	Closed	-$889K	–	1211
2024 Q4	$889K	Hold	23,000	–	–	﹤0.01%	1033
2024 Q3	$1.09M	Hold	23,000	–	–	﹤0.01%	1020
2024 Q2	$1.24M	Hold	23,000	–	–	﹤0.01%	992
2024 Q1	$1.57M	Hold	23,000	–	–	﹤0.01%	958
2023 Q4	$1.44M	Sell	23,000 -102,013	-82%	-$5.64M	﹤0.01%	959
2023 Q3	$5.67M	Sell	125,013 -1,768	-1%	-$91.3K	0.01%	724
2023 Q2	$7.12M	Buy	126,781 +98,770	+353%	+$5.6M	0.01%	710
2023 Q1	$1.27M	Buy	+28,011	New	+$1.36M	﹤0.01%	1028
2021 Q4	–	Sell	-19,570	Closed	-$2.19M	–	1418
2021 Q3	$2.19M	Buy	19,570 +7,460	+62%	+$937K	﹤0.01%	962
2021 Q2	$1.96M	Buy	+12,110	New	+$1.47M	﹤0.01%	1017

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Schroder Investment Management Group's CRSP Position: Q1 2025 in Review

Schroder Investment Management Group sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 23,000 shares — an estimated $889K sold.

Schroder Investment Management Group first reported a position in CRSP in Q2 2021 and held it in 10 quarters. The position peaked at $7.12M in Q2 2023. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

Schroder Investment Management Group reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
Schroder Investment Management Group sold 23,000 CRISPR Therapeutics shares in Q1 2025, an estimated $889K.
Schroder Investment Management Group first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 10 quarters.
Schroder Investment Management Group's CRISPR Therapeutics position peaked at $7.12M in Q2 2023.
396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Schroder Investment Management Group's 13F filing for Q1 2025, filed 13 May 2025.